创伤性脑病综合征患者伴或不伴阿尔茨海默病病理证据时的血浆P-tau181和P-tau217
研究检测了创伤性脑病综合征(TES)、阿尔茨海默病(AD)和健康对照者的血浆P-tau181和P-tau217。Aβ阳性TES患者血浆P-tau显著高于健康对照,P-tau217能较好区分Aβ阳性与Aβ阴性TES,但AD患者tau-PET摄取更高。血浆P-tau可能有助于识别TES中的AD病理,低水平可增加对CTE的怀疑。
要点
- Aβ阳性TES患者血浆P-tau181和P-tau217显著高于健康对照。
- 血浆P-tau217可较好区分Aβ阳性与Aβ阴性TES(AUC=0.79)。
- 低血浆P-tau水平可能增加临床对CTE而非AD作为主要病理的怀疑。
核心结论
- 血浆P-tau181和P-tau217检测可能是识别TES中AD病理的可行且可扩展的液体生物标志物。
- 低血浆P-tau水平可用于增加临床对CTE而非AD作为TES主要病理的怀疑。
- 目前不支持P-tau181或P-tau217作为CTE tau的体内生物标志物。
研究设计与样本
- 研究测量了TES患者、生物标志物确诊AD的轻度认知障碍/痴呆患者(AD)和健康对照(HC)的血浆P-tau181和P-tau217(Meso Scale Discovery电化学发光法)。
- 患者接受淀粉样蛋白β(Aβ)-PET,部分接受[18F]Flortaucipir tau-PET。
- 样本共131名参与者(TES N=18;AD N=65;HC N=48)。
- 对4例尸检确诊CTE的TES患者进行了定性描述。
主要发现
- Aβ阳性TES患者(N=10)血浆P-tau181(p<0.001,d=1.34)和P-tau217(p<0.001,d=1.59)显著高于HC,Aβ阴性TES无此差异。
- Aβ阳性TES较Aβ阴性TES血浆P-tau有升高趋势(P-tau181:p=0.06,d=1.06;P-tau217:p=0.09,d=0.93)。
- Aβ阳性TES与HC分类:P-tau181 AUC=0.87(0.71-1.00),P-tau217 AUC=0.93(0.86-1.00)。
- Aβ阳性TES与Aβ阴性TES区分:P-tau217 AUC=0.79(0.54-1.00,p=0.04),P-tau181 AUC=0.71(0.46-0.96,p=0.13)未达统计学显著。
- AD患者tau-PET摄取高于Aβ阳性TES,P-tau181 AUC=0.81(0.68-0.94),P-tau217 AUC=0.86(0.73-0.98)。
关键数值与推荐
- Aβ阳性TES与HC比较:P-tau181 p<0.001,d=1.34;P-tau217 p<0.001,d=1.59。
- Aβ阳性TES与Aβ阴性TES比较:P-tau181 p=0.06,d=1.06;P-tau217 p=0.09,d=0.93。
- Aβ阳性TES与HC的AUC:P-tau181 0.87(0.71-1.00),P-tau217 0.93(0.86-1.00)。
- Aβ阳性TES与Aβ阴性TES的AUC:P-tau217 0.79(0.54-1.00,p=0.04),P-tau181 0.71(0.46-0.96,p=0.13)。
- AD与Aβ阳性TES的AUC:P-tau181 0.81(0.68-0.94),P-tau217 0.86(0.73-0.98)。
临床怎么用
- 在TES患者中检测血浆P-tau181和P-tau217可能有助于识别AD病理。
- 低血浆P-tau水平可能用于增加临床对CTE而非AD作为主要病理的怀疑。
- 目前不支持将P-tau181或P-tau217用作CTE tau的体内生物标志物。
局限性
- 需要更大规模的对病理确诊CTE患者的研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Traumatic encephalopathy syndrome (TES) has overlapping clinical symptoms with Alzheimer disease (AD). AD pathology commonly co-occurs with chronic traumatic encephalopathy (CTE) pathology. There are currently no validated CTE biomarkers. AD-specific biomarkers such as plasma P-tau181 and P-tau217 may help to identify patients with TES who have AD pathology. METHODS: We measured plasma P-tau181 and P-tau217 (Meso Scale Discovery electrochemiluminescence) in patients with TES, mild cognitive impairment/dementia with biomarker-confirmed AD ("AD"), and healthy controls ("HC"). Patients underwent amyloid-beta (Aβ)-PET and a subset underwent tau-PET using [18F]Flortaucipir. We compared plasma P-tau levels controlling for age and sex and also performed AUC analyses to evaluate the accuracy of group differentiation. In patients with TES, we evaluated associations between plasma P-tau, years of repetitive head impact exposure, and tau-PET. Four TES patients with autopsy-confirmed CTE were described qualitatively. RESULTS: The sample included 131 participants (TES, N = 18; AD, N = 65; HC, N = 48). Aβ(+) patients with TES (N = 10), but not Aβ(-) TES, had significantly higher plasma P-tau levels than HC (P-tau181: p < 0.001, d = 1.34; P-tau217: p < 0.001, d = 1.59). There was a trend for Aβ(+) TES having higher plasma P-tau than Aβ(-) TES (P-tau181: p = 0.06, d = 1.06; P-tau217: p = 0.09, d = 0.93). AUC analyses showed good classification of Aβ(+) TES from HC for P-tau181 (AUC = 0.87 [0.71-1.00]) and P-tau217 (AUC = 0.93 [0.86-1.00]). Plasma P-tau217 showed fair differentiation of Aβ(+) TES from Aβ(-) TES (AUC = 0.79 [0.54-1.00], p = 0.04), whereas classification accuracy of P-tau181 was slightly lower and not statistically significant (AUC = 0.71 [0.46-0.96], p = 0.13). Patients with AD had higher tau-PET tracer uptake than Aβ(+) TES and were well differentiated using P-tau181 (AUC = 0.81 [0.68-0.94]) and P-tau217 (AUC = 0.86 [0.73-0.98]). Plasma P-tau correlated with the tau-PET signal in Aβ(+) TES but not in Aβ(-) TES, and there was no association between plasma P-tau and years of repetitive head impact exposure. TES patients with severe CTE and no AD at autopsy had low P-tau181 and P-tau217 levels. DISCUSSION: Measuring P-tau181 and P-tau217 in plasma may be a feasible and scalable fluid biomarker for identifying AD pathology in TES. Low plasma P-tau levels may be used to increase clinical suspicion of CTE over AD as a primary pathology in TES. Currently, there is no support for P-tau181 or P-tau217 as in vivo biomarkers of CTE tau. Larger studies of patients with pathologically confirmed CTE are needed. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that (1) among patients with TES and abnormal Aβ-PET scans, elevated plasma P-tau can differentiate between affected individuals and HCs; (2) low plasma P-tau may help identify patients with TES who do not have Alzheimer; and (3) plasma P-tau181 and P-tau217 are not useful biomarkers of patients with TES who do not have AD.
引用
- Asken BM, Tanner JA, VandeVrede L, et al. Plasma P-tau181 and P-tau217 in Patients With Traumatic Encephalopathy Syndrome With and Without Evidence of Alzheimer Disease Pathology. Neurology. 2022. PMID: 35577574. doi:10.1212/WNL.0000000000200678
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。